RU95109908A - PHARMACEUTICAL COMPOSITION - Google Patents

PHARMACEUTICAL COMPOSITION

Info

Publication number
RU95109908A
RU95109908A RU95109908/14A RU95109908A RU95109908A RU 95109908 A RU95109908 A RU 95109908A RU 95109908/14 A RU95109908/14 A RU 95109908/14A RU 95109908 A RU95109908 A RU 95109908A RU 95109908 A RU95109908 A RU 95109908A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
composition according
polysorbate
receptor antagonist
polyoxyethylene
Prior art date
Application number
RU95109908/14A
Other languages
Russian (ru)
Other versions
RU2126262C1 (en
Inventor
Бенджамин К. Сабадос
Original Assignee
Амген Боулдер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амген Боулдер Инк. filed Critical Амген Боулдер Инк.
Priority claimed from PCT/US1993/008802 external-priority patent/WO1994006457A1/en
Publication of RU95109908A publication Critical patent/RU95109908A/en
Application granted granted Critical
Publication of RU2126262C1 publication Critical patent/RU2126262C1/en

Links

Claims (14)

1. Фармацевтическая композиция, состоящая из антагониста рецептора ИЛ-1 и неионного сурфактанта.1. A pharmaceutical composition consisting of an IL-1 receptor antagonist and a nonionic surfactant. 2. Фармацевтическая композиция по п. 1, в которой антагонист рецептора ИЛ-1 и неионный сурфактант находятся в примерном весовом соотношении 100 : 1. 2. The pharmaceutical composition according to claim 1, wherein the IL-1 receptor antagonist and non-ionic surfactant are in an approximate weight ratio of 100: 1. 3. Фармацевтическая композиция по п. 1, в которой антагонист рецептора ИЛ-1 и неионный сурфактант находятся в примерном весовом соотношении 1000 : 1. 3. The pharmaceutical composition according to claim 1, wherein the IL-1 receptor antagonist and non-ionic surfactant are in an approximate weight ratio of 1000: 1. 4. Фармацевтическая композиция по п. 1, в которой антагонист рецептора ИЛ-1 и неионнный сурфактант находятся в примерном весовом соотношении 10 000 : 1. 4. The pharmaceutical composition according to claim 1, wherein the IL-1 receptor antagonist and nonionic surfactant are in an approximate weight ratio of 10,000: 1. 5. Фармацевтическая композиция по п. 1, в которой неионный сурфактант выбран из группы, содержащей блок-сополимеры этиленоксида и пропиленоксида, блок-сополимеры пропиленоксида и этиленоксида, сорбитанмонолаурат, сложный эфир сорбита, сложный эфир жирной кислоты полиглицерина, кокамид ДЕА лаурилсульфат, алконоламид, стеарат полиоксиэтилен пропиленгликоля, лауриловый эфир полиоксиэтилена, цетиловый эфир полиоксиэтилена, полисорбат, моностеарат глицерина, дистеарат глицерина, монопальмитат сорбита, сорбитанмоноолеат полиоксиэтилена, сорбитанмонолаурат полиоксиэтилена и моностеарат полипропиленгликоля. 5. The pharmaceutical composition according to claim 1, wherein the nonionic surfactant is selected from the group consisting of block copolymers of ethylene oxide and propylene oxide, block copolymers of propylene oxide and ethylene oxide, sorbitan monolaurate, sorbitol ester, polyglycerol fatty acid ester, cocamide DEA lauryl sulfate, alkonol polyoxyethylene propylene glycol stearate, polyoxyethylene lauryl ether, polyoxyethylene cetyl ether, polysorbate, glycerol monostearate, glycerol distearate, sorbitan monopalmitate, polyoxyethylene sorbitan monooleate, s polyoxyethylene orbitan monolaurate and polypropylene glycol monostearate. 6. Фармацевтическая композиция по п. 1, в которой указанный неионный сурфактант представляет собой полисорбат. 6. The pharmaceutical composition according to claim 1, wherein said non-ionic surfactant is polysorbate. 7. Фармацевтическая композиция по п.6, в которой указанный полисорбат представляет собой полисорбат 80. 7. The pharmaceutical composition according to claim 6, wherein said polysorbate is polysorbate 80. 8. Фармацевтическая композиция по п. 7, в которой указанный полисорбат 80 используют в концентрации 0,1%. 8. The pharmaceutical composition according to claim 7, wherein said polysorbate 80 is used at a concentration of 0.1%. 9. Фармацевтическая композиция по п. 1, в которой неионный сурфактант представляет собой Pluronic. 9. The pharmaceutical composition according to claim 1, wherein the nonionic surfactant is Pluronic. 10. Фармацевтическая композиция по п. 1, дополнительно содержащая буфер, который выбран из группы, включающей фосфатный буфер, цитратный буфер и ацетатный буфер. 10. The pharmaceutical composition of claim 1, further comprising a buffer that is selected from the group consisting of phosphate buffer, citrate buffer, and acetate buffer. 11. Фармацевтическая композиция, состоящая из антагониста рецептора ИЛ-1 и усилителя вязкости. 11. A pharmaceutical composition consisting of an IL-1 receptor antagonist and a viscosity enhancer. 12. Фармацевтическая композиция по п. 11, в которой усилитель вязкости представляет собой полиэтиленгликоль. 12. The pharmaceutical composition according to claim 11, in which the viscosity enhancer is a polyethylene glycol. 13. Фармацевтическая композиция, состоящая из 4,9 вес.% ингибитора ИЛ-1, 0,006 вес.% лимонной кислоты, 0,29 вес.% цитрата натрия, 0,82 вес.% хлорида натрия и 0,019 вес.% ЭДТА. 13. A pharmaceutical composition consisting of 4.9 wt.% IL-1 inhibitor, 0.006 wt.% Citric acid, 0.29 wt.% Sodium citrate, 0.82 wt.% Sodium chloride and 0.019 wt.% EDTA. 14. Фармацевтическая композиция, состоящая из 19,0 вес. % ингибитора ИЛ-1, 0,006 вес.% лимонной кислоты, 0,82 вес.% хлорида натрия и 0,019 вес.% ЭДТА. 14. A pharmaceutical composition consisting of 19.0 weight. % inhibitor of IL-1, 0.006 wt.% citric acid, 0.82 wt.% sodium chloride and 0.019 wt.% EDTA.
RU95109908A 1992-09-17 1993-09-17 Pharmaceutical composition RU2126262C1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US94700692A 1992-09-17 1992-09-17
US07/947006 1992-09-17
US07/947,006 1992-09-17
PCT/US1993/008802 WO1994006457A1 (en) 1992-09-17 1993-09-17 Pharmaceutical formulations of interleukin-1 inhibitors

Publications (2)

Publication Number Publication Date
RU95109908A true RU95109908A (en) 1997-12-10
RU2126262C1 RU2126262C1 (en) 1999-02-20

Family

ID=25485348

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95109908A RU2126262C1 (en) 1992-09-17 1993-09-17 Pharmaceutical composition

Country Status (19)

Country Link
EP (1) EP0661992B1 (en)
JP (1) JP3626755B2 (en)
KR (1) KR950703358A (en)
AT (1) ATE257389T1 (en)
AU (1) AU675969B2 (en)
CA (1) CA2141953C (en)
CZ (1) CZ291261B6 (en)
DE (1) DE69333378T2 (en)
DK (1) DK0661992T3 (en)
ES (1) ES2213744T3 (en)
FI (1) FI951250A (en)
HU (1) HU219445B (en)
NO (1) NO321453B1 (en)
NZ (1) NZ256328A (en)
PL (1) PL175705B1 (en)
PT (1) PT661992E (en)
RO (1) RO113528B1 (en)
RU (1) RU2126262C1 (en)
WO (1) WO1994006457A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
ATE508733T1 (en) * 1996-03-04 2011-05-15 Penn State Res Found MATERIALS AND METHODS FOR INCREASE CELLULAR INTERNALIZATION
CA2273852C (en) 1996-12-06 2009-09-29 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
ES2907826T3 (en) 2001-06-26 2022-04-26 Amgen Inc Antibodies to OPGL
JP4610154B2 (en) * 2002-05-30 2011-01-12 大塚製薬株式会社 Injectable preparation
NZ605429A (en) 2002-09-06 2014-08-29 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
US10765747B2 (en) * 2004-04-02 2020-09-08 Swedish Orphan Biovitrum Ab (Publ) Methods of reducing aggregation of IL-1ra
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
JP2008120722A (en) * 2006-11-10 2008-05-29 Benesis Corp Placebo for use with biologic
WO2009062339A1 (en) 2007-11-14 2009-05-22 General Regeneratives, Ltd. Methods of using interleukin-1 receptor antagonist as a myeloprotective agent
WO2009100406A2 (en) * 2008-02-07 2009-08-13 Synta Pharmaceuticals Corp. Topical formulations for the treatment of psoriasis
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN101690801B (en) 2009-10-26 2012-08-01 上海交通大学 Application of interleukin-1 receptor antagonist and medicinal composition thereof
JP2013510834A (en) 2009-11-16 2013-03-28 メリテク [1,5] -diazocine derivatives
HUE063115T2 (en) 2010-07-29 2023-12-28 Buzzard Pharmaceuticals AB Chimeric il-1 receptor type i antagonists
WO2012078101A1 (en) * 2010-12-07 2012-06-14 Swedish Orphan Biovitrum Ab (Publ) Method for the treatment of il-1 mediated diseases
RU2599848C2 (en) * 2011-02-11 2016-10-20 Сведиш Орфан Биовитрум Аб (Пабл) Citrate free pharmaceutical compositions comprising anakinra
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
CA2843197A1 (en) * 2011-07-29 2013-02-07 Eleven Biotherapeutics, Inc. Purified proteins
PL2968468T3 (en) 2013-03-13 2021-12-20 Buzzard Pharmaceuticals AB Chimeric cytokine formulations for ocular delivery
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
CA3002786C (en) * 2015-10-30 2021-09-07 Bonac Corporation Composition stably containing single-stranded nucleic acid molecule that suppresses expression of tgf-.beta.1 gene
WO2018022982A1 (en) 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5416568B2 (en) * 1972-09-29 1979-06-23
JPS537491B2 (en) * 1972-09-30 1978-03-18
AU9106491A (en) * 1991-01-17 1992-08-27 Upjohn Company, The Method of preventing and treating insulin dependent diabetes mellitus

Similar Documents

Publication Publication Date Title
RU95109908A (en) PHARMACEUTICAL COMPOSITION
KR950703358A (en) PHARMACEUTICAL FORMULATIONS OF INTEREUKIN-1 INHIBITORS
US5292502A (en) Non-irritating dentifrice
JP3446214B2 (en) Liquid transparent oral composition
AR015715A1 (en) A HAIR CONDITIONING COMPOSITION
RU99100327A (en) SURFACE-ACTIVE SYSTEM FOR STIMULATION OF ANTIBACTERIAL ABSORPTION ON DENTIN
CA2284000A1 (en) Hydrophilic binary systems for the administration of cyclosporine
MX9305535A (en) COMPOSITIONS AND CONCENTRATES GERMICIDES BASED ON IODINE-DETERGENT, WATER AND STABLE.
JP2002255771A (en) Liquid composition for oral cavity not mixed with alcohol
EE05533B1 (en) Pharmaceutical composition and preparation containing micronized drospirenone and 'strogen and their use
JPH0747531B2 (en) Oral composition
RU99113343A (en) MEDICINAL FORMS OF CYCLOSPORIN FOR ORAL ADMINISTRATION
DE69736739D1 (en) Stabilized growth hormone preparation and method for its preparation
JP2002537242A5 (en)
JPS56110612A (en) Readily disintegrable and absorbable compression molded article of slightly soluble drug
TW327602B (en) A pharmaceutical composition of an ophthalmic suspension containing difluprednate
KR840005020A (en) Corticosteroid external preparations
FR2665155B1 (en) BASIC ANTISUDORAL BASIC ALUMINUM ACTIVE COMPOUNDS, ANTISUDORAL COMPOSITIONS CONTAINING SUCH INGREDIENTS, AND METHODS OF PREPARING SUCH PRODUCTS AND COMPOSITIONS.
DE69101152D1 (en) Poly (alpha-hydroxy acrylic acid) and derivatives as anti-tartar active ingredients in oral compositions.
AR007549A1 (en) COMPOSITION OF SOAP OF FATTY ACIDS IN BARS CONTAINING SYNTHETIC SURFACTANTS
IT1249696B (en) PHARMACEUTICAL COMPOSITIONS CONTAINING FURAN DERIVATIVES AND PROCEDURE TO PREPARE THEM.
DE3773440D1 (en) PHARMACEUTICAL COMPOSITIONS FOR SUPPOSITORIES.
DE69205839D1 (en) Dermatological and cosmetic composition.
RU99114019A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DERIVATIVES N-SULFONILINDOLINE
RU97107154A (en) WATER COMPOSITIONS CONTAINING CYPROFLOXACIN, THEIR APPLICATION AND METHOD FOR PRODUCING